Liver specialist. Alumnus Dept. of Hepatology-PGIMER Chandigarh/ Dept. of Medicine AIIMS New Delhi/ AIIMS Raipur.
Joined July 2021
- Tweets 2,758
- Following 1,107
- Followers 971
- Likes 3,253
33 Photos and videos
Pinned Tweet
1 Jul 2025
A dream that began years ago has finally come true — Dr. Ashwin P Vinod, MBBS, MD (Medicine), DM (Hepatology) it is!
Endless gratitude to Dept. of Hepatology, PGIMER & its incredible faculty for shaping my journey.
Thank you all for being part of this dream. @HepatologyPGI
10 May 2022
6 mon back, I made this doodle, took a print-out and stuck it on the ceiling just above my bed. Today I am one step closer to that dream.
Rank 1, Hepatology INI SS. Cheers to 3 years of residency @ PGI Chandigarh, the Mecca of Hepatology in India. @HepatologyPGI
#Hepatology
5
2
82
6,361
Dr. Ashwin Pachaatt Vinod retweeted
We now have anti-inflammatory tools:
✅ Colchicine (LoDoCo2, COPE trials)
✅ IL-1β inhibition (Canakinumab)
✅ SGLT2i (pleiotropic anti-inflammatory effects)
✅ GLP-1RA (emerging anti-inflammatory data)
Treating inflammation is no longer optional in high-risk patients
1
12
31
974
Dr. Ashwin Pachaatt Vinod retweeted
Este documento de la BSG es como un libro de texto sobre endoscopia digestiva alta y es una lectura imprescindible para endoscopistas y médicos en formación 💡🆕
#SEPD2026
29
86
5,210
Dr. Ashwin Pachaatt Vinod retweeted
Jun 11
🔬 HCC biomarkers are advancing fast — but getting them to the clinic is a whole different challenge.
A timely review by Botía Martínez-Artero et al. just published in @JHEP_Reports.
👉 US AFP detects early HCC in only 47% — and <10% of at-risk patients complete surveillance
👉 GALAD & HES V2.0 lead the way; liquid biopsy panels are catching up
👉 AFP remains the only validated predictive biomarker in clinical practice
👉 Scientific validation alone isn't enough — regulatory approval, reimbursement & guideline inclusion must follow
Botía Martínez-Artero B, et al. JHEP Reports2026. Full text: doi.org/10.1016/j.jhepr.2026…
@ILCAnews @myESMO @ASCO @EASLnews #HCC #LiverCancer #Biomarker #LiquidBiopsy #AFP #Surveillance
9
17
1,193
Dr. Ashwin Pachaatt Vinod retweeted
Jun 10
32
128
5,246
Dr. Ashwin Pachaatt Vinod retweeted
ONLINE NOW: Foxp3 Tregs in HCC immunity and immunotherapy dlvr.it/TSxTHk
3
6
658
Dr. Ashwin Pachaatt Vinod retweeted
🔥 Excited to share our work on CVD risk assessment in MASLD
In NHANES III (n=3,475), higher CVD risk scores predicted long-term all-cause and cardiovascular mortality, with PREVENT showing strong risk stratification
@KarnJUVE
shorturl.at/Gcaf3
1
8
15
919
Dr. Ashwin Pachaatt Vinod retweeted
🆕 JCEH
**Predicting recompensation in decompensated cirrhosis**
In alcohol-, HBV- & HCV-related disease, identifying who may truly recompensate can sharpen counselling, follow-up intensity and LT timing.
doi.org/10.1016/j.jceh.2026.…
5
5
387
Dr. Ashwin Pachaatt Vinod retweeted
#livertwitter Check out our recent review on Primary Sclerosing Cholangitis
sciencedirect.com/science/ar…
@PSCSupportUK @UoBinfectionsch @uhbtrust @unibirm_CMH
1
22
68
4,133
Original Article: Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer (phase 3 RASolute 302 trial) nej.md/4nWaxvM
#ASCO26 | @ASCO
ALT A two-panel line graph shows overall survival in two populations, comparing darovasertib (blue line) and chemotherapy (gray line) treatments. Panel A depicts the RAS G12 population, while Panel B shows the overall population. Hazard ratios and confidence intervals are detailed in each panel.
ALT This image shows two line graphs titled "Progression-free Survival in the RAS G12 Population" and "Progression-free Survival in the Overall Population." Both graphs compare survival rates over 13 months between two groups: one receiving darovasertib and the other receiving chemotherapy. Accompanying the graphs are tables detailing the number of events and patients at risk for each treatment group.
8
348
1,199
69,319
Dr. Ashwin Pachaatt Vinod retweeted
Exploring role of therapeutic plasma exchange for hepatitis A-related acute liver failure: An Indian multi-center cohort study
Asisha M. Janeela, CE Eapen et al
@ajay_duseja @docMPK @drshalimar @drsuniltaneja #Livertwitter
link.springer.com/article/10…
10
14
850
Dr. Ashwin Pachaatt Vinod retweeted
Jun 1
RAS finally getting drugged is one of the great stories in modern biology, and almost nobody outside oncology understands why it's such a big deal.
YOU'LL LEARN SOMETHING AWESOME TODAY.
i am going to keep this as understandable (and simple) as i can.
OPEN THE THREAD.
🧵
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
25
424
1,655
265,391
Presented at #ASCO26:
Among patients with previously treated metastatic pancreatic ductal adenocarcinoma, the RAS(ON) inhibitor daraxonrasib led to significantly longer overall survival and progression-free survival than chemotherapy. Full phase 3 RASolute 302 trial results: nej.md/4nWaxvM
@ASCO
ALT Graph from a study published in the New England Journal of Medicine on daraxonrasib versus chemotherapy for metastatic pancreatic cancer. The x-axis represents months, and the y-axis shows the percentage of patients alive. Two lines indicate survival rates: daraxonrasib (blue) and chemotherapy (gray). The bottom section lists patients at risk over time. Title and journal logo are included.
52
2,055
5,576
2,470,884
Dr. Ashwin Pachaatt Vinod retweeted
🧫 New multisociety consensus on PSVD
🗣️ L. Elkrief | #EASLCongress
🔬 PSVD & NCPF now interchangeable
⚠️ Biopsy mandatory | can be diagnosed WITHOUT portal hypertension
💡 First globally endorsed framework (EASL/AASLD/APASL/ALEH)
🔗 journal-of-hepatology.eu/art…
1
37
57
3,154
Dr. Ashwin Pachaatt Vinod retweeted
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
92
1,273
6,504
1,151,927
Dr. Ashwin Pachaatt Vinod retweeted
May 26
Inaccurate stocks data on Chatgpt/Claude? That was one of the problems I wanted to solve.
I've been trading for close to a decade. Every day I'd have screens open in one tab, chatbots in another, NSE site for filings,… x.com/i/web/status/204829374…
3
16
59,070
Dr. Ashwin Pachaatt Vinod retweeted
May 25
The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer.
✓ out the new Ground Truths (link in profile)
65
757
2,571
707,413
Dr. Ashwin Pachaatt Vinod retweeted
Checking out the phase 3 TRIUMPH-1 topline results for #retatrutide 👉
investor.lilly.com/news-rele…
Topline results from @EliLillyandCo highlight a couple of things to celebrate 🎉
👉Baseline BMI 40 means we are helping a patient population who has been marginalized previously and who have had relatively fewer options for meaningful weight loss (eg, bariatric surgery)
👉 Almost 30% mean #weightloss at the highest retatrutide dose is approximating what we achieve with #bariatricsurgery
🛑Notes of caution
👉 It's silly when companies downplay side effects with a handwaving statement of "generally consistent with trials of other incretin-based therapies"
👉 We don't have head-to-head comparison to tirzepatide, but FOR CONTEXT, tirzepatide had ~HALF the rate of constipation and vomiting
Takeaways
⭐️Trial design here really informs intended patient population
⭐️Retatrutide 12 mg is slated to be a genuine alternative to bariatric surgery for this patient population with severe #obesity
⭐️Side effect management will be key to tolerability and long-term #weightmanagement
5
7
26
1,967
Dr. Ashwin Pachaatt Vinod retweeted
May 21
🚨 Gut Online
1st RCT of 304 patients w/ mild-to-moderate acute cholangitis, urgentERCP (<24h) did NOT reduce 30D mortality vs earlyERCP (24–48h) but a/w with highr postERCP advrse events.
Maybe “earlier” isnot always “better”.
#ERCP #Endoscopy #GI #Gastroenterology #Cholangitis
12
58
143
15,393
Dr. Ashwin Pachaatt Vinod retweeted
Today, we shared new data from the latest Phase 3 study of retatrutide, an investigational treatment being studied for adults with obesity or overweight with at least one weight-related comorbidity.
Learn more: go.lilly.com/ow76mw
4
20
68
29,206